Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT05524961 Recruiting - Parkinson Disease Clinical Trials

Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease

Start date: December 9, 2022
Phase: N/A
Study type: Interventional

This is a randomized placebo- and active-controlled trial for assessing the efficacy of bright light therapy for sleep and mood symptoms in patients with Parkinson's disease

NCT ID: NCT05523570 Recruiting - Parkinson's Disease Clinical Trials

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension

Start date: August 22, 2022
Phase: Phase 1
Study type: Interventional

This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.

NCT ID: NCT05518617 Recruiting - Parkinson Disease Clinical Trials

Molecular and Functional Imaging in Monogenic PD.

FOX_1
Start date: July 1, 2022
Phase:
Study type: Observational

In this study, the investigators aim to find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of PD symptoms.

NCT ID: NCT05516732 Recruiting - Parkinson Disease Clinical Trials

Serotonin Release in Premotor and Motor PD

FOX3
Start date: July 1, 2022
Phase:
Study type: Observational

In this study, the investigators aim to provide a deeper understanding of Parkinson's disease and find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of Parkinson's disease symptoms

NCT ID: NCT05516719 Recruiting - Parkinson Disease Clinical Trials

Longitudinal Investigation of I2BS in PD

FOX_2
Start date: November 1, 2021
Phase:
Study type: Observational

In this study, the researchers aim to find a biomarker of PD. Using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The PET and SPECT scans use small amounts of radiation and specific compounds called tracers, to study chemical changes in the brain in a way not possible with any other procedure. The MRI uses magnetic fields to generate images of brain structure and function

NCT ID: NCT05513794 Recruiting - Parkinson Disease Clinical Trials

Prospective Study for Neuromelanin Image Analysis

Start date: November 2, 2022
Phase: N/A
Study type: Interventional

In order to develop an image analysis system that automatically detects and quantifies neuromelanin, this study aims to construct a database of a wide sample by collecting brain MRI neuromelanin images prospectively.

NCT ID: NCT05510739 Recruiting - Parkinson Disease Clinical Trials

Support for Physical Activity in Everyday Life With Parkinson's Disease

STEPS-PD
Start date: September 19, 2022
Phase: N/A
Study type: Interventional

This study aims to determine the effects of a motor-cognitive exercise intervention, delivered in the home environment using eHealth methods, among people with Parkinson's disease. The intervention will support and motivate motor training, combined with cognitive training, aimed at attentional and executive functions, among people at mild-moderate disease stages. The main hypothesis is that unsupervised motor-cognitive training in the home environment using eHealth will lead to improvements in gait performance, increased physical activity levels and improved perceived health.

NCT ID: NCT05505019 Recruiting - Parkinson Disease Clinical Trials

Targeting Apathy With Music in Parkinson's Disease

Start date: February 9, 2022
Phase: N/A
Study type: Interventional

Parkinson's Disease (PD) is often accompanied by non-motor symptoms that make treatment more difficult. One such symptom is apathy (lack of motivation and emotion). There are no treatments for apathy in PD, and this remains a major unmet need in PD patients. One possible way to target apathy in PD patients is listening to music, which has been shown to help improve apathy in older adults. Little work has explored the mechanism in which music targets apathy. Thus, the goal of this study is to understand how music listening can impact the brain towards decreasing apathy in PD patients.

NCT ID: NCT05502055 Recruiting - Parkinson Disease Clinical Trials

Perspectives on Healthcare Access and Equity of People With Parkinson's Disease Identifying as LGBTQ+

LGBTQ+_PD
Start date: October 18, 2022
Phase:
Study type: Observational

Study Rationale: Older adults who identify as lesbian, gay, bisexual, transgender, or queer (LGBTQ+) have worse health than non-LGBTQ+ older adults. They and their care partners face greater barriers to getting healthcare and support from friends and family. This is because of lifelong stigma, discrimination, and isolation often separated from their families. Parkinson disease (PD) is a disease that usually appears in older age, so there may be many LGBTQ+ elders with PD, but there is currently no information on how people with PD who are LGBTQ+ are coping with their disease and aging. This study will begin to clarify their needs. Hypothesis/Research Question: What are the experiences and perspectives of LGBTQ+ people living with PD, their care partners, and physicians managing people with PD? Study Design: The investigators will interview 20 people with PD, half who identify as LGBTQ+ and half who are not. The investigators will also interview their care partners and physicians who treat people with PD. From the responses to the interview questions, investigators will create a survey that will be sent to people across the country. Impact on Diagnosis/Treatment of Parkinson's Disease: By understanding what LGBTQ+ people with PD need, and what ideas they have for improving their healthcare, better systems for meeting their needs can be built. Next Steps for Development: With this understanding, future work can focus on educating healthcare providers and clinics to improve the ways they talk with and treat LGBTQ+ people with PD.

NCT ID: NCT05499572 Recruiting - Usability Clinical Trials

Usability of Levodopa Cyclops™ vs INBRIJA® in Parkinson's Patients

DPI-6
Start date: February 29, 2024
Phase:
Study type: Observational

Currently there is one Levodopa inhaler on the market, the INBRIJA® inhaler. When looking at the user instructions for the INBRIJA®, multiple steps are necessary including preparing and cleaning the inhaler. The Levodopa Cyclops™ inhaler also requires steps to be ready-for-use, however there are less steps required to reach this 'ready-for-use' state. This is mainly because the medicine (Levodopa) is already prefilled in the inhaler. Moreover, the Levodopa Cyclops™ is a single-use inhaler and cleaning steps are not necessary. Since both inhalers should be used during off episodes, there might be a preference for one inhaler over the other due to the instructions. An off episode might impair the ability and length to successfully operate an inhaler due to mental or mobility issues. This study investigates if Parkinson patients have a preference for one of the inhalers based on handling steps, ease-of-use, understandability.